cd24 extracellular domain-igg1 fc domain recombinant fusion protein cd24fc
Dyslipidemias
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)protein_peptidePhase 2Dormant
D
29/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 14/ 100
- Competitive Position
- 95/ 100
Competitive context
21 Active assets in the Dyslipidemias cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lipitor Johns Hopkins University | Phase 4 | A |
Rosuvastatin Korea University Anam Hospital | Phase 4 | A |
Metformin RenJi Hospital | Phase 4 | BBB |
Lipitor National Institute of Kidney Disease and Urology (NIKDU) | Phase 4 | BBB |
Ezetimibe Samsung Medical Center | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
cd24 extracellular domain-igg1 fc domain recombinant fusion protein cd24fc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →